Covered recipient · General Payments record
KHENG JOE LAU
Allopathic & Osteopathic Physicians Internal Medicine Endocrinology, Diabetes & Metabolism
General Payments · PY2022–2024
$1,412.06
- Reported across 30 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Travel and Lodging | $783.70 | 4 |
| Food and Beverage | $400.23 | 12 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $973.39 | 8 |
| Novo Nordisk AS | $107.84 | 3 |
| Lilly USA, LLC | $31.59 | 1 |
| Xeris Pharmaceuticals, Inc. | $30.70 | 2 |
| DEXCOM, INC. | $22.39 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.02 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.02 | 06/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117891253 | CMS |
| Dexcom, Inc. | $22.39 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1153314474 | CMS |
| Lilly USA, LLC | $31.59 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135135442 | CMS |
| Medtronic, Inc. | $9.74 | 03/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117085403 | CMS |
| Medtronic, Inc. | $34.25 | 08/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117085407 | CMS |
| Medtronic, Inc. | $254.40 | 08/06/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117085409 | CMS |
| Medtronic, Inc. | $34.25 | 08/07/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117085405 | CMS |
| Medtronic, Inc. | $83.95 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117085413 | CMS |
| Medtronic, Inc. | $48.00 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117085415 | CMS |
| Medtronic, Inc. | $48.00 | 09/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117085417 | CMS |
| Medtronic, Inc. | $460.80 | 10/19/2024 | Travel and Lodging | Undisputed | 01/23/2026 | 1117085411 | CMS |
| Novo Nordisk Inc | $62.48 | 05/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097322807 | CMS |
| Novo Nordisk Inc | $25.00 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097336505 | CMS |
| Novo Nordisk Inc | $20.36 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097220173 | CMS |
| Xeris Pharmaceuticals, Inc. | $16.11 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144601743 | CMS |
| Xeris Pharmaceuticals, Inc. | $14.59 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1144601745 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.